Synalgos DC | 956595-89-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Synalgos DC
• 英文别名: (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol;2-acetyloxybenzoic acid;1,3,7-trimethylpurine-2,6-dione
• CAS: 956595-89-4
• 化学式: C35H41N5O9
• 分子量: 675.7
• InChiKey: GQJWWXHBAXYBNA-CCLYOLAMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.01
• 重原子数：
  49
• 可旋转键数：
  4
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  164
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
  申请人：——

  公开号：US20040176469A1

  公开（公告）日：2004-09-09

  Effects of deprenyl or propargylamine compounds (MAO inhibitors) and novel compositions comprising at least one MAO inhibitor and at least one antiinflammatory agent such as nonsteroidal antiinflammatory drugs (NSAIDS), steroids, acetaminophen (COX-3 inhibitors), 5-lipoxygenase inhibitors, leukotriene receptor antagonists, leukotriene A4 hydrolase inhibitors, antihistaminics, histamine 2 receptor antagonists, phosphodiesterase-4 antagonists, cytokine antagonists, CD44 antagonists, antineoplastic agents, 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins), estrogens, androgens, antiplatelet agents, antidepressants, Helicobacter pylori inhibitors, proton pump inhibitors, thiazolidinediones, dual-action compounds, combinations of these drugs with other agents, derivatives and metabolites of synthetic and natural antiinflammatory agents. The compounds and compositions protect against gastrointestinal, renal and other toxicities induced by antiinflammatory agents, and enhance the beneficial effects of these drugs. Effects of MAO inhibitors such as 1-deprenyl co-administered with antiinflammatory drugs or chemically attached to antniinflammatory drugs are disclosed. Therapeutic methods of using MAO inhibitors and antiinflammatory drugs for the prevention and treatment of inflammatory disorders, pain, fever, cancer, gastrointestinal lesions, and a variety of cardiac, cerebral and peripheral disorders are disclosed.

  去甲肾上腺素或丙炔胺化合物（MAO 抑制剂）的作用，以及由至少一种 MAO 抑制剂和至少一种抗炎剂（如非甾体抗炎药 (NSAIDS)、类固醇、对乙酰氨基酚（COX-3 抑制剂）、5-脂氧合酶抑制剂、白三烯受体拮抗剂、白三烯 A4 水解酶抑制剂、抗组胺剂、组胺 2 受体拮抗剂、磷酸二酯酶-4 拮抗剂、细胞因子拮抗剂、CD44 拮抗剂）组成的新型组合物的作用、白三烯 A4 水解酶抑制剂、抗组胺药、组胺 2 受体拮抗剂、磷酸二酯酶-4 拮抗剂、细胞因子拮抗剂、CD44 拮抗剂、抗肿瘤药、3-羟基-3-甲基戊二酰辅酶 A 抑制剂（他汀类）、雌激素、雄激素、抗血小板药、抗抑郁药、 幽门螺旋杆菌 抑制剂、质子泵抑制剂、噻唑烷二酮类化合物、双效化合物、这些药物与其他药物的复方制剂、合成和天然抗炎药物的衍生物和代谢产物。这些化合物和组合物能防止抗炎药物引起的胃肠道、肾脏和其他毒性反应，并能增强这些药物的有益作用。本研究公开了 MAO 抑制剂（如 1-deprenyl）与抗炎药物联合用药或与抗炎药物化学连接的效果。公开了使用 MAO 抑制剂和抗炎药物预防和治疗炎症、疼痛、发热、癌症、胃肠道病变以及各种心、脑和外周疾病的治疗方法。
• US8519005B2
  申请人：——

  公开号：US8519005B2

  公开（公告）日：2013-08-27